MSP-2020 is developed by Otsuka Pharmaceutical Development & Commercialization, Inc..

Last reviewed 2026-04-19 · How we verify

MSP-2020

Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase 1 active Small molecule

At a glance

Generic name	MSP-2020
Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MSP-2020 CI brief — competitive landscape report
MSP-2020 updates RSS · CI watch RSS
Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI